Surgical Innovation & Prudent Investment

by

It is a truth universally acknowledged, that an investor in possession of good sense, must be in search of opportunities. Presently, much excitement surrounds the advancements in artificial intelligence, and a degree of apprehension regarding its potential for speculative excess. One observes, however, that while enthusiasm may occasionally run ahead of demonstrable benefit, the underlying principle of seeking improvements in established practices is rarely unwise. Indeed, the application of these complex programs to the field of surgery presents a particularly intriguing prospect, one which, though yet in its infancy, promises to reshape the capabilities of the medical profession.

Should one perceive the merit of such an undertaking, one is not alone. The assistance of automated systems is already becoming commonplace in the operating theatre. Two companies, it appears, are particularly well-positioned to benefit from this evolution: Intuitive Surgical and Medtronic. A judicious consideration of each is, therefore, warranted.

Intuitive Surgical: A Singular Focus

For those who anticipate a substantial advancement in surgical techniques through the application of artificial intelligence, a company dedicated solely to the development of surgical robotics may prove a suitable investment. Intuitive Surgical, a pioneer in this domain, has concentrated its efforts entirely upon this single pursuit. In the past year, the company installed 1,721 of its da Vinci surgical systems, a respectable increase of nearly 13% over the previous period. The total number of such systems in operation now stands at 11,106, reflecting a year-over-year increase of 12%. A considerable number, to be sure, and one which suggests a growing acceptance of this technology amongst the surgical community.

Loading widget...

Demand for these systems amongst patients is demonstrably strong, with an 18% increase in the number of procedures performed utilizing the da Vinci system in the past year. The company anticipates a further increase of as much as 15% in the coming year. More recently, the approval by the regulatory authorities of an artificial intelligence tool to assist surgeons in performing lung surgery is a noteworthy development, indicating a practical application of these advancements. It is not, perhaps, an extravagant suggestion that the data generated by these systems could be further employed to refine and improve the capabilities of the artificial intelligence itself. Indeed, one might even envision a future in which the da Vinci system operates with a degree of autonomy. For the more adventurous investor, a purchase of Intuitive Surgical at this juncture might prove advantageous, though one must acknowledge that the current valuation, with a price-to-earnings ratio of 67, is not inconsiderable.

Medtronic: A Diversified Proposition

Should one prefer a more diversified portfolio and a more moderate valuation, Medtronic presents a viable alternative. As one of the largest medical device companies in the world, with interests spanning cardiovascular health, neuroscience, diabetes management, and surgical robotics, Medtronic offers a broader range of opportunities. It is noteworthy, however, that the company intends to spin off its diabetes division in the near future. In terms of valuation, Medtronic’s price-to-earnings ratio of 27, while not entirely without significance, is considerably more reasonable than that of Intuitive Surgical.

While Medtronic may not be quite as far along in the deployment of its surgical robots as Intuitive Surgical, the same opportunities presented by the da Vinci system also apply to the Hugo system. Furthermore, a Medtronic investment offers an additional benefit not found with Intuitive Surgical: a dividend. The current yield is 2.8%, and the company has consistently increased its dividend for an impressive 48 consecutive years. This is a circumstance which, one imagines, will appeal to the more conservative investor, particularly when compared to the yield of the broader S&P 500 index, which currently stands at a mere 1.1%.

Loading widget...

The intended spin-off of Medtronic’s diabetes division is a development which should not be overlooked. The move is intended to improve the company’s profitability and growth prospects. A timely decision, perhaps, and one which warrants prompt consideration.

Securing a Position in the Future

It is not yet the case that artificial intelligence is independently performing surgical procedures. However, it is clear that considerable effort is being directed towards achieving this goal. Should – and one suspects when – this becomes a reality, Intuitive Surgical and Medtronic are likely to be prominently involved, given their existing expertise in surgical robotics. To secure a position before this advancement fully takes hold might prove a prudent course of action.

Read More

2026-01-31 00:53